PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:PLx Pharma Inc (PLXP) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013957
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:41
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
PLx Pharma Inc (PLx Pharma) is a drug development company that develops patent-protected delivery systems. The company’s products include PLxGuard delivery system, PLxGuard pipeline products, PL2200 aspirin and PL1100 and PL1200 ibuprofen products. Its PLxGuard delivery system are used in enhancement of efficacy of drugs, GI safety development, new or extended patent protection, and new drug application solutions. PLx Pharma offers publications and research services. The company serves for severe pain and cardiovascular market. It caters its products and services to healthcare professionals. PLx Pharma is headquartered in Houston, Texas, the US.

PLx Pharma Inc (PLXP) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deal Details 12
Venture Financing 12
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Merger 16
Dipexium Pharma Merges with PLx Pharma 16
Licensing Agreements 18
PLx Pharma Enters into Licensing Agreement with Lee’s Pharma for Cardiovascular Product 18
Equity Offering 19
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc – Key Competitors 22
PLx Pharma Inc – Key Employees 23
PLx Pharma Inc – Locations And Subsidiaries 24
Head Office 24
Recent Developments 25
Financial Announcements 25
Nov 09, 2017: PLx Pharma Reports Third Quarter 2017 Results 25
Aug 10, 2017: PLx Pharma Reports Second Quarter 2017 Results 27
May 02, 2017: Rita M. O Connor Appointed Chief Financial Officer of PLx Pharma 28
Corporate Communications 29
May 01, 2017: PLx Pharma appoints vice president of sales and marketing 29
Jan 04, 2016: PLx Pharma Appoints Natasha Giordano as CEO 30
Product News 31
06/20/2016: Dipexium Pharmaceuticals Locilex Microbiology Data Presented at ASM Microbe 2016 Conference 31
05/10/2017: PLx Pharma Receives NCI Grant for Research of Novel Aspirin Formulation to Prevent Colorectal Cancer 32
05/01/2017: PLx Pharma Appoints Michael J. Dillon as Vice President, Sales and Marketing 33
Product Approvals 34
Oct 04, 2016: Dipexium Receives European Medicines Agency Designation as a Small and Medium Enterprise 34
Clinical Trials 35
Feb 14, 2017: PLx Pharma Announces Publication of Positive Antiplatelet Data for Aspertec in Peer-Reviewed Medical Journal JACC 35
Oct 25, 2016: Dipexium Announces Top-line Data from OneStep Phase 3 Trials with Locilex in Mild Diabetic Foot Infection Did Not Meet Primary Clinical Endpoint of Superiority Versus Vehicle Plus Standardized Wound Care 36
Oct 20, 2016: Dipexium Provides Update on Availability of Results from Pivotal Phase 3 Clinical Trials with Locilex 37
May 16, 2016: Dipexium Announces Completion of Enrollment Objective in OneStep-1 Pivotal Phase 3 Clinical Trial 38
May 12, 2016: Dipexium Pharmaceuticals Announces Completion of Enrollment Objective in OneStep-2 Pivotal Phase 3 Clinical Trial 39
Feb 04, 2016: Dipexium Pharmaceuticals Reaches 75% Enrollment Milestone in Pivotal Phase 3 Clinical Trials 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41

List of Tables
PLx Pharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2014 2
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PLx Pharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PLx Pharma Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PLx Pharma Inc, Medical Devices Deals, 2011 to YTD 2017 10
PLx Pharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PLx Pharma Raises USD1.3 Million in Venture Financing 12
PLx Pharma Raises USD9 Million in Extended Series E Financing 13
PLx Pharma Raises USD8.27 Million in Series E Financing 14
PLx Pharma Secures US$2.9 Million In Series F Round 15
Dipexium Pharma Merges with PLx Pharma 16
PLx Pharma Enters into Licensing Agreement with Lee's Pharma for Cardiovascular Product 18
PLx Pharma Raises USD18.2 Million in Private Placement of Shares 19
PLx Pharma Withdraws IPO 20
PLx Pharma Inc, Key Competitors 22
PLx Pharma Inc, Key Employees 23

★海外企業調査レポート[PLx Pharma Inc (PLXP)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Factor Therapeutics Ltd (FTT)-製薬・医療分野:企業M&A・提携分析
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor w …
  • NKT AS (NKT):企業の財務・戦略的SWOT分析
    NKT AS (NKT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Eickhoff Corporation
    Eickhoff Corporation - Strategy, SWOT and Corporate Finance Report Summary Eickhoff Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • BreitBurn Energy Partners L.P. (BBEP)-石油・ガス分野:企業M&A・提携分析
    Summary BreitBurn Energy Partners L.P. (BreitBurn Energy) is an independent upstream oil and gas partnership company that acquires assets, and explores, develops and produces oil and gas properties in the US. The company’s asset portfolio consist of producing and non-producing oil, Natural Gas Liqui …
  • Partners Innovation Fund LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary Partners Innovation Fund LLC (PIF), a subsidiary of Partners HealthCare System Inc focuses to invest in healthcare companies based on intellectual property created within its research community. The company provides capital to seed and early stage medical devices, diagnostics, digital health …
  • Uni-President China Holdings Ltd:企業の戦略・SWOT・財務分析
    Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Uni-President China Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Michigan Public Power Agency:企業の発電所・SWOT分析2018
    Michigan Public Power Agency - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • ShotSpotter Inc (SSTI):企業の財務・戦略的SWOT分析
    ShotSpotter Inc (SSTI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Trinity Health:企業の戦略的SWOT分析
    Trinity Health - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • The Tata Power Co Ltd (TATAPOWER):企業の財務・戦略的SWOT分析
    The Tata Power Co Ltd (TATAPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Passenger Rail Agency of South Africa:企業の戦略的SWOT分析
    Passenger Rail Agency of South Africa - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and maj …
  • Finnair Oyj:企業のM&A・事業提携・投資動向
    Finnair Oyj - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Finnair Oyj Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Sequana SA (SEQ):企業の財務・戦略的SWOT分析
    Sequana SA (SEQ) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Adamis Pharmaceuticals Corp (ADMP)-製薬・医療分野:企業M&A・提携分析
    Summary Adamis Pharmaceuticals Corp (Adamis), formerly Cellegy Pharmaceuticals Inc is a biopharmaceutical company that offers therapies. The company develops and commercializes products in the therapeutic areas of allergy and respiratory diseases. Its pipeline product, epinephrine pre-filled syringe …
  • AMETEK Inc (AME):企業の財務・戦略的SWOT分析
    Summary AMETEK Inc (AMETEK) is an electronic products manufacturing company that manufactures electronic instruments and electromechanical devices. The company's products portfolio include medical materials, motion control systems, sub assemblies and connectors, electrical cord reels, gauges, titani …
  • Pharmsynthez (LIFE):製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmsynthez is a pharmaceutical company that manufactures and markets generic active pharmaceutical ingredients. The company offers production and sales of both officinal medicines (original OM) and active pharmaceutical ingredients (API). It offers drugs such as vazostenon, glaumax, cathal …
  • PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis – Q4, 2017
    PDC Energy Inc Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2017 Summary PDC Energy Inc (PDC Energy) is an oil and gas company that offers production, development, exploration and marketing of crude oil, natural gas and natural gas liquids. The company provides horizontal …
  • Adris grupa dd:企業の戦略・SWOT・財務分析
    Adris grupa dd - Strategy, SWOT and Corporate Finance Report Summary Adris grupa dd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Cintas Corp (CTAS):企業の財務・戦略的SWOT分析
    Cintas Corp (CTAS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Pareteum Corp (TEUM):企業の財務・戦略的SWOT分析
    Pareteum Corp (TEUM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆